Warning: fopen(/home/virtual/epih/journal/upload/ip_log/ip_log_2025-07.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 95 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 96 Trends in gastrointestinal cancer incidence in Iran, 2001-2010: a joinpoint analysis
Skip Navigation
Skip to contents

Epidemiol Health : Epidemiology and Health

OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Articles

Page Path
HOME > Epidemiol Health > Volume 38; 2016 > Article
Original Article
 Trends in gastrointestinal cancer incidence in Iran, 2001-2010: a joinpoint analysis
Mehdi Darabi1orcid, Mohsen Asadi Lari1,2orcid, Seyed Abbas Motevalian1orcid, Ali Motlagh3, Shahram Arsang-Jang4orcid, Maryam Karimi Jaberi1
Epidemiol Health 2016;38:e2016056.
DOI: https://doi.org/10.4178/epih.e2016056
Published online: December 5, 2016

1Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran

2Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran

3Department of Radiotherapy, Shahid Baheshti University of Medical Sciences, Tehran Iran

4Department of Epidemiology and Biostatistics, Faculty of Health, Qom University of Medical Sciences, Qom, Iran

Correspondence: Mohsen Asadi Lari Department of Epidemiology, School of Public Health, Iran University of Medical Sciences. Shahid Hemmat Highway, Tehran 1449614535, Iran Tel: +98-2186703209, Fax: +98-2188622608, E-mail: mohsen.asadi@yahoo.com
• Received: November 21, 2016   • Accepted: December 5, 2016

©2016, Korean Society of Epidemiology

This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next
  • 21,108 Views
  • 339 Download
  • 29 Web of Science
  • 19 Crossref
  • 36 Scopus
Full Article

Download PDF Download PDF

  • OBJECTIVES
    The main purpose of this study was to evaluate changes in the time trends of stomach, colorectal, and esophageal cancer during the past decade in Iran.
  • METHODS
    Cancer incidence data for the years 2001 to 2010 were obtained from the cancer registration of the Ministry of Health. All incidence rates were directly age-standardized to the world standard population. In order to identified significant changes in time trends, we performed a joinpoint analysis. The annual percent change (APC) for each segment of the trends was then calculated.
  • RESULTS
    The incidence of stomach cancer increased from 4.18 and 2.41 per 100,000 population in men and women, respectively, in 2001 to 17.06 (APC, 16.7%) and 8.85 (APC, 16.2%) per 100,000 population in 2010 for men and women, respectively. The corresponding values for colorectal cancer were 2.12 and 2.00 per 100,000 population for men and women, respectively, in 2001 and 11.28 (APC, 20.0%) and 10.33 (APC, 20.0%) per 100,000 in 2010. For esophageal cancer, the corresponding increase was from 3.25 and 2.10 per 100,000 population in 2001 to 5.57 (APC, 12.0%) and 5.62 (APC, 11.2%) per 100,000 population among men and women, respectively. The incidence increased most rapidly for stomach cancer in men and women aged 80 years and older (APC, 23.7% for men; APC, 18.6% for women), for colorectal cancer in men aged 60 to 69 years (APC, 24.2%) and in women aged 50 to 59 years (APC, 25.1%), and for esophageal cancer in men and women aged 80 years and older (APC, 17.5% for men; APC,15.3% for women) over the period of the study.
  • CONCLUSIONS
    The incidence of gastrointestinal cancer significantly increased during the past decade. Therefore, monitoring the trends of cancer incidence can assist efforts for cancer prevention and control.
  • Keywords: Incidence, Gastrointestinal neoplasms, Trends, Joinpoint, Iran
Cancer is an important public health challenge in Iran, as well as in most countries worldwide [1]. In Iran, after cardiovascular diseases and accidents, cancer is the third most common cause of death. Although the rate of cancer incidence in developed countries is generally two times greater than that in developing countries, the number of people affected by cancer yearly in developing countries is higher, and their disease is also more deadly [2]. Cancer in Iran shows considerably different patterns than those that exist in developed countries. For example, stomach and esophageal cancers, which are the most prevalent types of cancer in Iran, are much less common in some other countries, especially the US, where they are not among the top 10 prevalent types of cancer [3]. In this study, we used cancer registration data. Cancer registration is a tool for measuring cancer incidence in a defined population during a specific period of time in order to evaluate and control for the effects of cancer in society [4]. The obtained data can be used for studying trends in cancer incidence, trends, patient follow-up, and survival [5]. Moreover, cancer registration is an important part of cancer control programs, and registration data can be used widely in etiologic research, evaluation of the effects of preventive measures, and program development in healthcare services [6]. Stomach, colorectal, and esophageal cancers have a high incidence among Iranian men and women; colorectal and stomach cancers are among the five most prevalent cancers, and esophageal cancer is among the 10 most prevalent cancers.
Iran is experiencing changes in age demographics, economic development, and social transformations, which can have significant effects on cancer patterns and changes in cancer trends. The main purpose of the current study was to evaluate the time trends of age-standardized incidence rates (ASRs) and identify changes in the incidence of gastrointestinal cancers (stomach, colorectal, and esophageal) from 2001 to 2010.
The cancer incidence statistics for 2001 to 2010 were obtained from the National Cancer Control Program in Iran (Ministry of Health). The Iran cancer registry program is designed to register all cancer cases in the country. All pathology centers and other information sources such as hospitals’ medical records, mortality data from provincial governments, hematology-oncology centers, radiotherapy centers, and so on are obliged to report their data to the Cancer Office of Disease Control and Prevention (CDC). The CDC then annually enters the data in a computer program, identifies duplicates and reconciling the new data with the data from previous years. The executive arms of the program include all medical universities in the country. The three cancer sites included in this study were defined according to the International Classification of Diseases, 10th revision. Stomach cancer was defined by code C16, esophageal cancer by code C15, and colorectal cancer by codes C18 to C21. We used ASRs in order to compare populations with different age structures, with weights obtained from the world standard population [7]. We then compared the incidence rates for five specific age groups (40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years and older).
For analysis, we used joinpoint regression analysis to identify the years when significant changes took place in the ASRs. Joinpoint regression analysis fits a series of joined straight lines to the ASRs on a log scale [8]. Straight line segments are joined at joinpoints, where the incidence trend changes its slope to a statistically significant extent. We allowed a maximum of two joinpoints, and an overall significance level of 5% was used for the comparisons of models applied to each data series. The best-fitting model was estimated separately for men and women. The Joinpoint version 4.2.0.2 (https://surveillance.cancer.gov/joinpoint/) was used for the statistical analysis.
Stomach cancer
For stomach cancer, a significant increase in incidence was observed for both men and women, with annual percent changes (APCs) of 16.7% (95% confidence interval [CI], 14.6 to 18.8%) and 16.2% (95% CI, 7.7 to 25.4%), respectively, from 2001 to 2010. The ASR for men was higher than for women (Table 1). In men, the incidence significantly increased from 2001 to 2008; however, this trend changed in 2008, after which no significant increase was observed. However, in women, the incidence increased throughout the study period (Figure 1). In men and women, the highest incidence changes were observed in the age group of 80 years old above and higher (APC, 23.7% for men; APC, 18.6% for women) (Table 2). The ASRs of stomach cancer by birth cohort is plotted in Figure 2. The incidence increased as the birth cohort advanced, with more substantial increases in later birth cohorts for both men and women.
Colorectal cancer
For colorectal cancer, a significant increase was found in both men and women during the study period, but the trend did not differ between men and women (APC, 20% for both men and women) (Table 1). The incidence trend for both groups significantly increased from 2001 to 2008, and then became approximately stable. The decrease in men was greater than the decrease in women (Figure 1). In men, the highest APC was found in the age group of 60 to 69 years, and in women, the highest APC was found in the age group of 50 to 59 years (APC, 24.2% for men; APC, 25.1% for women) (Table 2). The ASRs of colorectal cancer by birth cohort are plotted in Figure 2. The incidence increased in later birth cohorts for both men and women.
Esophageal cancer
A significant increase in the incidence of esophageal cancer in men and women was observed from 2001 to 2010 (APC, 12% for men; APC, 11.2% for women) (Table 1). No difference in the trend of the incidence rate of esophageal cancer was found between men and women. A significantly increasing trend was found from 2001 to 2008, while it decreased from 2008 to 2010 (Figure 1). In both men and women, the highest increase in the APC was observed individuals 80 years of age or older (APC, 17.5% in men; APC, 15.3% in women) (Table 2). The ASIRs of esophageal cancer by birth cohort are plotted in Figure 2. The incidence increased in later birth cohorts in both men and women.
This study documented the incidence of gastrointestinal cancers in Iran during a 10-year period. The cancers studied showed an increasing trend during the study period. Two reasons for this increase can be proposed: first, changes in lifestyle and food patterns to become more similar to those of Western countries, and second, improvements in the diagnosis and registration of cancer cases.
Evidence indicates that Helicobacter pylori is a cause of stomach cancer, and the decreasing trend of stomach cancer in developed countries has been found to be significantly related to the decrease of infections with this bacterium. The International Agency for Research on Cancer has reported that H. pylori is the main reason for stomach cancer [9]. The prevalence of this bacterium in developing countries, such as Iran, is 80%, whereas its prevalence in developed countries is 30% [10]. Therefore, the main reason for the increase in stomach cancer among Iranians is likely to be infections with this bacterium. The 5% decrease in the incidence trend of this cancer in men from 2008 to 2010 may have been related to the increase of antibiotic use to treat H. pylori infections. In most studies, it has been reported that salt and salty foods can increase the incidence of this cancer, while the consumption of fruits, fresh vegetables, and fish can have a protective effect [11-13]. Although a healthy diet including fruits and vegetables prevails in Iran, in comparison with developed countries, in recent decades it has been observed that dietary trends are moving toward Western foods, such as conserved and fast foods [14].
Smoking is a risk factor for gastrointestinal cancers. In a cohort study, it was reported that the risk of stomach cancer in smokers was twice that in non-smokers, and in the majority of studies, a significant relationship between smoking and cancer was found [15-17]. In general, the trend in stomach cancer incidence is decreasing simultaneously with the trend of smoking in developed countries, while these trends are concomitantly increasing in developing countries. Although we do not have exact information about smoking trends in the last decade in Iran, data about smoking in the 1990s in the country indicated that cigarette smoking prevalence decreased overall from 11.7 to 14.6% among individuals 15 to 69 years of age [18]. It seems that smoking has not had a major effect on stomach cancer incidence in Iran. Men gender is a risk factor for stomach cancer. In the current study, the incidence of stomach cancer in men was much higher than that in women. In some studies, this difference has been attributed to the protective role of woman hormones [19].
Many studies have shown an increase in stomach cancer in Iran. Haidari et al. [20] found that the overall incidence rate of stomach cancer increased from 2.8 per 100,000 in 2000 to 9.1 per 100,000 in 2005; moreover, Sadjadi et al. [21] in Ardabil province documented increase in the incidence of stomach cancer. Another study in Tehran and Shiraz indicated that the overall occurrence of stomach cancer slightly increased (0.08 for Tehran, and 0.03 for Shiraz) [22]. While Iran is facing an increase in the incidence of stomach cancer, other research has suggested a decrease in stomach cancer incidence in some countries, such as Cyprus, Jordan, Egypt, South America, and European locations such as Spain and the state of Amberia in Italy. The decline in the incidence of stomach cancer in the US and Western Europe may have resulted from H. pylori infection control and the impact of cancer control programs.
According to GLOBOCAN 2012, colorectal cancer in Iran is the fourth most prevalent cancer among men and the second most prevalent among women [23]. In a systematic review in Iran, the ASRs of colorectal cancer were 8.16 per 100,000 and 6.17 per 100,000 for men and women, respectively [24]. Najafi et al. [25] showed that the incidence of colorectal cancer in 1993 to 2007 increased by 14%, which is consistent with our results. Additionally, in a report from Fars province, the ASR for colon cancer among men was 1.61 per 100,000 from 1970 to 1980 and 4.20 per 100,000 from 1990 to 2000, with a significant annual increase of 0.13 per 100,000 (p<0.05) [26]. Yazdizadeh et al. [22] concluded that the incidence of colon cancer increased in Fars and Tehran provinces during the past 30 years. The magnitude of this increase, as measured by comparing the last five years to the first five years, was 82% for Tehran and 65% for Shiraz.
In some European studies, colorectal cancer showed a trend of increasing incidence from 1984 to 2007 [27,28]. Moreover, in some Asian countries, such as China, Japan, South Korea, and Singapore, a 2-fold to 4-fold increase in colorectal cancer has been reported during the past decades [29]. Similarly, the current study detected a considerable increase in cancer incidence among men and women during the study period.
Diet plays an important role in the development of colorectal cancer. Several cohort studies have revealed that consuming a considerable amount of fruits, vegetables, fish, and high-fiber foods can greatly decrease the incidence of this cancer [30,31]. One of the reasons for the increasing trend of colorectal cancer in Iran may be changes in dietary habits. Fast foods, which are typical of Western foods, are increasingly replacing Iranian traditional foods, which are mostly high in fiber [32]. Studies conducted in Iran have indicated that fat consumption increased greatly from 1990 to 2000, and that this increase was accompanied by an increase in the obesity rate [33,34]. Obesity, especially in the abdominal region, increases the risk of colorectal cancer by up to 40% in men and 16% in women [35]. Physical activity and maintaining an ideal weight can lead to a significant decrease in the incidence of colorectal cancer, as physically active people are 20 to 30% less affected by this cancer [36]. Only 31% of the mature population of Iran engages in regular physical activity [14]. Consequently, obesity and inadequate physical activity are other reasons for the increased incidence of colorectal cancer among Iranians. Previous studies in North America indicated that the risk of cancer for 15 to 20% of the population can be attributed to smoking habits [36]. The smoking prevalence in the mature population of Iran is approximately 14% [14]. In addition, colorectal cancer incidence increases with age. The risk of colorectal cancer increases slightly after 40 years of age, but after 50, it increases rapidly [11,37]. Such a pattern was observed in the current study; that is, the most positive trend of incidence was identified in men and women who were born in 1923 (age group of 80 to 84 years).
Iran is considered to be a country in the esophageal cancer belt, with a high incidence of this disease , and the highest incidence rates have been reported from northern provinces such as Mazandaran, Golestan, and Khorasan [38]. According to studies, Gonbad-e Kavus in Golestan province, with an incidence rate of 100 per 100,000 individuals, has one of the greatest cancer incidence rates in Iran and the world. In contrast, Kerman province, with an incidence rate of three per 100,000 individuals, is considered to have a low risk by worldwide standards [39].
Esophageal cancer is related to smoking habits and alcohol consumption. These factors, as well as the low consumption of fruits and vegetables, may account for 89% of the cases of this disease [40]. According to previous studies, the rate of esophageal cancer incidence in northeastern regions of Golestan province has decreased by half during the last 35 years. This considerable decrease took place after great improvements in the economic, social, and cultural status of the area [41]. The reasons for high rates of esophageal cancer incidence in Iran’s northeast have been analyzed in various studies during the past three decades, especially the last 10 years. The main reasons have been identified as drinking hot tea, not consuming enough fruits and vegetables, using drugs and their derivatives, drinking unhealthy water, and poverty. Moreover, genetic factors among the population of that area (Iran’s northeast) have been established as another reason for the high prevalence of this cancer [42-44].
Many studies in Iran have shown a reduced incidence of esophageal cancer. The majority of such studies were conducted before 2000. In contrast, our study identified an increased incidence during the study period. Part of this inconsistency may be due to differences in survey techniques and the size of the population studied. During the 1970s, the diagnosis of esophageal cancer was confirmed histologically in approximately 27% of cases [45], while in 2009 histological conformation was performed in 86% of cases [46]. It is likely, therefore, that the results obtained at that point reflected an overestimation of the true diagnosis of esophageal cancer. Improved diagnostic facilities, with greater accessibility of endoscopy for the diagnosis and the exact localization of upper gastrointestinal cancer, which plays a particularly important role in distinguishing cardia cancer from distal esophageal cancer, may be another reason for the decrease in esophageal cancer found in previous studies.
Part of the observed changes in the incidence of gastrointestinal cancer may be related to improved diagnostic techniques and more efficient registration. Until 2004, the cancer registry was only based on pathology reports. Subsequently, the population-based registration program in Iran expanded. According to a report of the Iranian Ministry of Health, the coverage of the cancer registry in Iran has increased from 18% in 1999 to 81% in 2005 [46]. A study in Italy showed that a high proportion of the increase in the incidence of stomach cancer was related to improvements in diagnostic techniques and the cancer registry system [47]. Additionally, previous studies in Iran have explicitly discussed the improvement in the cancer registry in Iran [48,49].
Gastrointestinal cancers showed a trend of increasing incidence in both genders from 2000 to 2010. The observed trends are associated with changes in lifestyle, socioeconomic conditions, and increased life expectancy. Therefore, it is essential to place a primary focus on prevention methods in order to reduce the incidence of cancer.
We are grateful to the Disease Management Center of the Ministry of Health.

The authors have no conflicts of interest to declare for this study.

Figure 1.
Trends in the age-standardized incidence rate (ASR) for gastrointestinal cancers (A: stomach, B: colorectal, and C: esophageal) in Iran, 2001-2010.
epih-38-e2016056f1.gif
Figure 2.
Trends in the age-standardized incidence rate (ASR) of gastrointestinal cancers (A:stomach, B: colorectal, and C: esophageal) by age group.
epih-38-e2016056f2.gif
Table 1.
CRs and ASRs for gastrointestinal cancers in men and women in Iran, 2001-2010
Cancer site Men
 Women
2001
 2010
 2001
 2010
No. of cases CR ASR No. of cases CR ASR APC No. of cases CR ASR No. of cases CR ASR APC
Stomach 1,105 3.3 4.18 5,192 13.2 17.06 16.7* 484 1.5 2.41 2,238 6.5 8.85 16.2*
Colorectal 379 1.3 2.12 3,443 8.8 11.28 20.0* 344 1.2 2.00 2,641 7.7 10.33 20.0*
Esophageal 858 2.5 3.25 1,693 4.3 5.57 12.0* 405 1.3 2.10 1,378 4.0 5.62 11.2*

CR, crude rates (per 100,000); ASR, age-standardized incidence rates (per 100,000); APC, annual percent change of ASRs.

* p<0.05.

Table 2.
Trends in the ASRs for gastrointestinal cancers in Iranian men and women according to a joinpoint analysis by age group (2001-2010)
Cancer site, age APC (95% Cl) 2001-2010 Trend 1 APC (95% CI) Trend 2 APC (95% CI) Trend 3 APC (95% CI)
Men
 Stomach
  40-49 12.4 (0.6, 25.7) 2001-2003 54.2 (-21.8, 204.0) 2003-2008 11.9 (-9.7, 38.7) 2008-2010 -17 (-57.9, 63.7)
  50-59 9.8 (6.3, 13.3) 2001-2003 41.4 (16.4, 71.7) 2003-2008 10.2 (3.6, 17.2) 2008-2010 -15.6 (-30.5, 2.5)
  60-69 12.3 (6.5, 18.4)* 2001-2003 41.5 (6.5, 88.0)* 2003-2010 5.1 (1.2, 9.2) N/A N/A
  70-79 16.6 (12.4, 21.0) 2001-2003 63.4 (30.6, 104.4) 2003-2008 9.6 (2.1, 17.6) 2008-2010 -2.9 (-22.3, 21.5)
  80+ 23.7 (14.3, 33.9) 2001-2004 63.6 (26.3, 112.0) 2004-2010 7.6 (-1.5, 17.4) N/A N/A
  All 16.7 (14.6, 18.8)* 2001-2003 70.4 (52.6, 90.3)* 2003-2008 8.9 (5.1, 12.8)* 2008-2010 -5.1 (-15.0, 6.0)
 Colorectal
  40-49 13.0 (10.4, 15.6)* 2001-2003 46.7 (27.6, 68.6)* 2003-2008 15.1 (10.1, 20.3)* 2008-2010 -16.9 (-27.7, -4.5)*
  50-59 17.2 (11.8, 22.8)* 2001-2003 52.9 (15.0, 103.3)* 2003-2008 17.6 (7.5, 28.7)* 2008-2010 -11.0 (-33.1, 18.3)
  60-69 24.2 (16.1, 32.9)* 2001-2003 62.3 (13.1, 133.1)* 2003-2010 15.1 (9.7, 20.8)* N/A N/A
  70-79 21.0 (15.4, 26.9)* 2001-2004 43.1 (22.7, 66.9)* 2004-2010 11.3 (5.6, 17.2)* N/A N/A
  80+ 21.2 (11.9, 31.3)* 2001-2007 35.9 (24.4.8, 48.4)* 2007-2010 -3.6 (-25.7, 25.2) N/A N/A
  All 20.0 (15.6, 24.6)* 2001-2003 63.3 (30.0, 105.1)* 2003-2008 15.9 (7.8, 24.5)* 2008-2010 -3.8 (-23.4, -0.7)
 Esophageal
  40-49 9.2 (-6.0, 26.8) 2001-2004 42.8 (-10.0, 126.5) 2004-2008 6.2 (-33.1, 38.4) 2008-2010 -22.9(-69.4, 94.1)
  50-59 12.5 (6.5, 18.8)* 2001-2003 64.3 (17.6, 129.6)* 2003-2008 10.8 (-0.3, 23.2) 2008-2010 -20 (-42.7.2, 11.7)
  60-69 14.3 (6.2, 23.1)* 2001-2003 57.7 (6.4, 133.7)* 2003-2010 4.3 (-1.0, 9.9) N/A N/A
  70-79 13.4 (5.2, 22.2)* 2001-2005 31.7 (11.6, 55.5)* 2005-2010 0.6 (-10.6, 13.1) N/A N/A
  80+ 17.5 (6.4, 29.8)* 2001-2003 77.1 (-3.3, 224.4) 2003-2008 15.5 (-4.6, 39.9) 2008-2010 -18.6 (-55.6, 49.0)
  All 12.0 (6.6, 17.7)* 2001-2003 54.6 (14.1, 109.4)* 2003-2008 8.9 (-1.1, 19.9) 2008-2010 -12.8 (-35.7, 18.1)
Women
 Stomach
  40-49 12.1 (3.4, 21.6) 2001-2004 38.3 (13.0, 69.3) 2004-2008 12.3 (-6.3, 34.6) 2008-2010 -18.5 (-57.3, 55.3)
  50-59 14.6 (8.5, 21.0) 2001-2004 35.8 (13.8, 62.1) 2004-2010 5.3 (-0.9, 11.7) N/A N/A
  60-69 13.1 (5.9, 20.8)* 2001-2004 35.6 (9.5, 68.0)* 2004-2010 3.3 (-3.9, 11.0) N/A N/A
  70-79 16.1 (8.8, 23.9) 2001-2003 40.1 (-1.2, 98.7) 2003-2010 10.0 (5.0, 15.3) N/A N/A
  80+ 18.6 (13.9, 23.5) N/A N/A N/A N/A N/A N/A
  All 16.2 (7.7, 25.4)* 2001-2003 53.3 (2.1, 130.1)* 2003-2010 7.4 (1.7, 13.4)* N/A N/A
 Colorectal
  40-49 18.6 (8.3, 29.8)* N/A N/A N/A N/A N/A N/A
  50-59 25.1 (13.3, 38.2)* 2001-2003 69.3 (-0.3, 187.5) 2003-2010 14.8 (6.9, 23.2)* N/A N/A
  60-69 19.5 (13.3, 26.1)* 2001-2004 52.8 (28.5, 81.8)* 2004-2010 5.7 (-0.3, 12.1) N/A N/A
  70-79 20.2 (15.5, 25.1)* 2001-2004 48.3 (30.1,69.1)* 2004-2010 8.2 (3.6, 13.1)* N/A N/A
  80+ 23.0 (10.9, 36.6)* 2001-2004 60.4 (14.2, 125.3)* 2004-2010 7.8 (-3.9, 20.9) - -
  All 20.0 (18.8, 21.3)* 2001-2003 66.8 (56.4, 78.0)* 2003-2008 13.8 (11.5, 16.1)* 2008-2010 -1.3 (-7.5, 5.3)
 Esophageal
  40-49 6.5 (-1.8, 15.4) 2001-2003 62.7 (-0.4, 165.9) 2003-2008 1.9 (-1.7, 19.0) 2008-2010 -22.3 (-52.4, 27.0)
  50-59 14.0 (1.5, 28.2)* 2001-2003 52.8 (-18.2, 185.6) 2003-2010 4.9 (-3.5, 14.0) N/A N/A
  60-69 13.9 (5.6, 22.9)* 2001-2003 70.8 (14.0, 155.8)* 2003-2010 1.5 (-3.9, 7.1) N/A N/A
  70-79 12.6 (3.7, 22.4)* 2001-2003 52.3 (-8.1, 152.5) 2003-2008 9.7 (-6.5, 28.7) 2008-2010 -11.1 (-46.4, 47.4)
  80+ 15.3 (4.9, 26.8)* 2001-2003 28.7 (20.2, 37.7)* 2003-2010 -21.5(-52.7, 30.4) N/A N/A
  All 11.2 (6.2, 16.5)* 2001-2003 54.5 (16.7, 104.7)* 2003-2008 7.4 (-1.7, 17.4) 2008-2010 -12.7 (-34.1, 15.6)

ASR, age-standardized incidence rate; APC, annual percentage change of ASRs; CI, confidence interval; N/A, not applicable.

* p<0.05.

  • 1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.ArticlePubMed
  • 2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide; 2013 [cited 2016 Dec 20]. Available from: http://globocan.iarc.fr, accessed on day/month/year
  • 3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.ArticlePubMed
  • 4. Forman D, Bray F, Brewster DH, Mbalawa CG, Kohler B, Piñeros M, et al. Cancer incidence in five continents volume X; 2014 [cited 2016 Dec 20]. Available from: http://www.iarc.fr/en/publications/pdfs-online/epi/sp164/CI5volX_Full.pdf
  • 5. National Institutes of Health. Surveillance, Epidemiology, and End Results (SEER) Program. [cited 2016 Dec 20]. Available from: https://seer.cancer.gov/
  • 6. Muir CS, Percy C. Cancer registration: principles and methods. Classification and coding of neoplasms. IARC Sci Publ 1991;64-81.PubMed
  • 7. Segi M, Fujisaku S. Cancer mortality for selected sites in 24 countries (1950-1957). Sendai: Department of Public Health, Tohoku University School of Medicine; 1960. p 64-81.
  • 8. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000;19:335-351.ArticlePubMed
  • 9. EUROGAST Study Group. An international association between Helicobacter pylori infection and gastric cancer. Lancet 1993;341:1359-1362.ArticlePubMed
  • 10. Atherton JC. The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. Annu Rev Pathol 2006;1:63-96.ArticlePubMed
  • 11. World Cancer Research Fund; American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective; 2007 [cited 2016 Dec 20]. Available from: http://www.aicr.org/assets/docs/pdf/reports/Second_Expert_Report.pdf
  • 12. Matsuzaka M, Fukuda S, Takahashi I, Shimaya S, Oyama T, Yaegaki M, et al. The decreasing burden of gastric cancer in Japan. Tohoku J Exp Med 2007;212:207-219.ArticlePubMed
  • 13. Kim MK, Sasaki S, Sasazuki S, Tsugane S; Japan Public Health Center-based Prospective Study Group. Prospective study of three major dietary patterns and risk of gastric cancer in Japan. Int J Cancer 2004;110:435-442.ArticlePubMed
  • 14. Alikhani S, Delavari A, Alaedini F, Kelishadi R, Rohbani S, Safaei A. A province-based surveillance system for the risk factors of non-communicable diseases: a prototype for integration of risk factor surveillance into primary healthcare systems of developing countries. Public Health 2009;123:358-364.ArticlePubMed
  • 15. Roukos DH, Agnantis NJ, Fatouros M, Kappas AM. Gastric cancer: introduction, pathology, epidemiology. Gastric Breast Cancer 2002;1:1-3.
  • 16. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003;56:1-9.ArticlePubMed
  • 17. Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors. J Surg Oncol 2013;107:230-236.ArticlePubMed
  • 18. Mohammad K, Nourbala AA, Madjdzadeh R, Karimlou M. Trend of smoking prevalence in Iran from 1991 to 1999 based on two national health survey. Hakim Res J 2001;3:290-294. (Persian).
  • 19. Chandanos E, Lagergren J. Oestrogen and the enigmatic male predominance of gastric cancer. Eur J Cancer 2008;44:2397-2403.ArticlePubMed
  • 20. Haidari M, Nikbakht MR, Pasdar Y, Najaf F. Trend analysis of gastric cancer incidence in Iran and its six geographical areas during 2000- 2005. Asian Pac J Cancer Prev 2012;13:3335-3341.ArticlePubMed
  • 21. Sadjadi A, Malekzadeh R, Derakhshan MH, Sepehr A, Nouraie M, Sotoudeh M, et al. Cancer occurrence in Ardabil: results of a population-based cancer registry from Iran. Int J Cancer 2003;107:113-118.ArticlePubMed
  • 22. Yazdizadeh B, Jarrahi AM, Mortazavi H, Mohagheghi MA, Tahmasebi S, Nahvijo A. Time trends in the occurrence of major GI cancers in Iran. Asian Pac J Cancer Prev 2005;6:130-134.PubMed
  • 23. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. [cited 2016 Dec 20]. Available from: http://globocan.iarc.fr/Default.aspx
  • 24. Dolatkhah R, Somi MH, Kermani IA, Ghojazadeh M, Jafarabadi MA, Farassati F, et al. Increased colorectal cancer incidence in Iran: a systematic review and meta-analysis. BMC Public Health 2015;15:997.ArticlePubMedPMCPDF
  • 25. Najafi F, Mozaffari HR, Karami M, Izadi B, Tavvafzadeh R, Pasdar Y. Trends in incidence of gastrointestinal tract cancers in Western Iran, 1993-2007. Iran Red Crescent Med J 2011;13:805-810.PubMedPMC
  • 26. Hosseini SV, Izadpanah A, Yarmohammadi H. Epidemiological changes in colorectal cancer in Shiraz, Iran: 1980-2000. ANZ J Surg 2004;74:547-549.ArticlePubMed
  • 27. Mistry M, Parkin DM, Ahmad AS, Sasieni P. Cancer incidence in the United Kingdom: projections to the year 2030. Br J Cancer 2011;105:1795-1803.ArticlePubMedPMC
  • 28. Zavoral M, Suchanek S, Majek O, Fric P, Minarikova P, Minarik M, et al. Colorectal cancer screening: 20 years of development and recent progress. World J Gastroenterol 2014;20:3825-3834.ArticlePubMedPMC
  • 29. World Health Organization. Global status report on noncommunicable diseases 2010. [cited 2016 Dec 20]. Available from: http://www.who.int/nmh/publications/ncd_report_full_en.pdf
  • 30. Key TJ. Fruit and vegetables and cancer risk. Br J Cancer 2011;104:6-11.ArticlePubMedPMC
  • 31. Aune D, Lau R, Chan DS, Vieira R, Greenwood DC, Kampman E, et al. Nonlinear reduction in risk for colorectal cancer by fruit and vegetable intake based on meta-analysis of prospective studies. Gastroenterology 2011;141:106-118.ArticlePubMed
  • 32. Russell RM, Ismail-Beigi F, Reinhold JG. Folate content of Iranian breads and the effect of their fiber content on the intestinal absorption of folic acid. Am J Clin Nutr 1976;29:799-802.ArticlePubMed
  • 33. Azizi F, Allahverdian S, Mirmiran P, Rahmani M, Mohammadi F. Dietary factors and body mass index in a group of Iranian adolescents: Tehran lipid and glucose study--2. Int J Vitam Nutr Res 2001;71:123-127.ArticlePubMed
  • 34. Ghassemi H, Harrison G, Mohammad K. An accelerated nutrition transition in Iran. Public Health Nutr 2002;5:149-155.ArticlePubMed
  • 35. Donohoe CL, Pidgeon GP, Lysaght J, Reynolds JV. Obesity and gastrointestinal cancer. Br J Surg 2010;97:628-642.ArticlePubMed
  • 36. Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. Gastroenterology 2010;138:2029-2043. e10.ArticlePubMedPMC
  • 37. National Cancer Institute. SEER cancer statistics review, 1975-2005. [cited 2016 Dec 20]. Available from: https://seer.cancer.gov/archive/csr/1975_2005/
  • 38. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-831.ArticlePubMed
  • 39. Haghdoost AA, Hosseini H, Chamani G, Zarei MR, Rad M, Hashemipoor M, et al. Rising incidence of adenocarcinoma of the esophagus in Kerman, Iran. Arch Iran Med 2008;11:364-370.PubMed
  • 40. Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003;95:1404-1413.ArticlePubMed
  • 41. Semnani S, Sadjadi A, Fahimi S, Nouraie M, Naeimi M, Kabir J, et al. Declining incidence of esophageal cancer in the Turkmen Plain, eastern part of the Caspian Littoral of Iran: a retrospective cancer surveillance. Cancer Detect Prev 2006;30:14-19.ArticlePubMed
  • 42. Islami F, Pourshams A, Nasrollahzadeh D, Kamangar F, Fahimi S, Shakeri R, et al. Tea drinking habits and oesophageal cancer in a high risk area in northern Iran: population based case-control study. BMJ 2009;338:b929.ArticlePubMedPMC
  • 43. Nasrollahzadeh D, Kamangar F, Aghcheli K, Sotoudeh M, Islami F, Abnet CC, et al. Opium, tobacco, and alcohol use in relation to oesophageal squamous cell carcinoma in a high-risk area of Iran. Br J Cancer 2008;98:1857-1863.ArticlePubMedPMC
  • 44. Shafieezadeh T, Holakuei Naieni K, Fotohi A, Mahmoodi M. Familial aggregation of esophageal cancer in Babol district in the north of Iran. J Sch Public Health Inst Public Health Res 2006;4:57-64. (Persian).
  • 45. Mahboubi E, Kmet J, Cook PJ, Day NE, Ghadirian P, Salmasizadeh S. Oesophageal cancer studies in the Caspian Littoral of Iran: the Caspian cancer registry. Br J Cancer 1973;28:197-214.ArticlePubMedPMC
  • 46. Center for Disease Control and Prevention, Noncommunicable Deputy Cancer Office. Iranian annual national cancer registration report 2008-2009. Tehran: Ministry of Health and Medical Education; 2012. p 13. (Persian).
  • 47. Brunetti D, Tamaro P, Tiribelli M, Fanin R, Stanta G, Zanazzo GA, et al. Time trend in cancer incidence among 0-24 year-old residents of the Province of Trieste, Italy, 1972-2003. Epidemiol Prev 2009;33:161-168. (Italian).PubMed
  • 48. Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol 2009;20:556-563.ArticlePubMed
  • 49. Etemadi A, Sadjadi A, Semnani S, Nouraie SM, Khademi H, Bahadori M. Cancer registry in Iran: a brief overview. Arch Iran Med 2008;11:577-580.PubMed

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • Prevalence, trends, and characteristics of metabolic dysfunction-associated steatotic liver disease among the US population aged 12–79 years
      Tsung-Hua Shen, Chung-Hsuen Wu, Yuan-Wen Lee, Chun-Chao Chang
      European Journal of Gastroenterology & Hepatology.2024; 36(5): 636.     CrossRef
    • Prevalence, trends, and characteristics of polypharmacy among US pregnant women aged 15 to 44 years: NHANES 1999 to 2016
      Yu-Chien Chang, Hsin-Yi Huang, Tsung-Hua Shen, Chung-Hsuen Wu
      Medicine.2023; 102(22): e33828.     CrossRef
    • THE EFFECT OF PASSIVE MUSIC THERAPY ON THE QUALITY OF LIFE OF FAMILY CAREGIVERS OF CANCER PATIENTS UNDERGOING CHEMOTHERAPY REFERRING TO IMAM KHOMEINI UNIVERSITY HOSPITAL AT URMIA, IRAN IN 2022
      Samereh Eghtedar, Moloud Radfar, Yasin Shafipour, Vahid Alinejad
      Nursing and Midwifery Journal.2023; 20(12): 1014.     CrossRef
    • Investigating Trends of Incidence Rates of Esophageal Cancer Divided by Squamous Cell Carcinoma and Adenocarcinoma in Southern Iran: a 10-Year Experience
      Mahnaz Hosseini-Bensenjan, Hossein Molavi Vardanjani, Sezaneh Haghpanah, Zahra Khosravizadegan, Kamran Bagheri-Lankarani
      Journal of Gastrointestinal Cancer.2022; 53(1): 230.     CrossRef
    • Gastrointestinal Cancer Prevention Policies
      Neda Kabiri, Rahim Khodayari-zarnaq, Manouchehr Khoshbaten, Ali Janati
      International Journal of Preventive Medicine.2022; 13(1): 8.     CrossRef
    • A cost-effectiveness modeling study of treatment interventions for stage I to III esophageal squamous cell carcinoma
      Rajabali Daroudi, Azin Nahvijou, Mohammad Arab, Ahmad Faramarzi, Bita Kalaghchi, Ali Akbari Sari, Javad Javan-Noughabi
      Cost Effectiveness and Resource Allocation.2022;[Epub]     CrossRef
    • Significant Association of Variable Number Tandem Repeat Polymorphism rs58335419 in the MIR137 Gene With the Risk of Gastric and Colon Cancers
      Pegah Jafari, Sedighe Baghernia, Mehdi Moghanibashi, Parisa Mohamadynejad
      British Journal of Biomedical Science.2022;[Epub]     CrossRef
    • Mortality Trends of Gastrointestinal, Liver, and Pancreaticobiliary Diseases: A Hospital-Based Prospective Study in the Southeast of Iran
      Mohammad Javad Zahedi, Sara Shafieipour, Mohammad Mahdi Hayatbakhsh Abbasi, Mohsen Nakhaie, Mohammad Rezaei Zadeh Rukerd, Mohammad Mehdi Lashkarizadeh, Farbood Noorbini, Mohammad Hasan Baghaei, Abbas Pourjafari, Ebrahim Aminian, Fatemeh Karami Robati, Aza
      Middle East Journal of Digestive Diseases.2022; 14(4): 404.     CrossRef
    • Predictors of Colorectal Cancer Screening Participation in Southern Khorasan (Iran)
      Abbas Ali Ramazani, Ensiyeh Norozi, Hassan AmirabadiZadeh, Ali Reza Ehteshampour, Hamid Salehiniya
      Journal of Gastrointestinal Cancer.2021; 52(1): 187.     CrossRef
    • Incidence and Risk Factors of Colorectal Cancer in the Iranian Population: a Systematic Review
      Hossein Mozafar Saadati, Batool Okhovat, Farzad Khodamoradi
      Journal of Gastrointestinal Cancer.2021; 52(2): 414.     CrossRef
    • Serum level of programmed death-ligand 1 in patients with gastric cancer in Mazandaran Province as a High-Risk Region in Iran
      Ramin Shekarriz, Akbar Hedayatizadeh-Omran, Omolbanin Amjadi, Reza Alizadeh-Navaei, Gholamali Godazandeh
      Clinical Cancer Investigation Journal.2021; 10(1): 5.     CrossRef
    • Trend of Gastric Cancer Incidence in an Area Located in the Center of Iran: 2009–2014
      Rahmatollah Moradzadeh, Ali Arash Anoushirvani
      Journal of Gastrointestinal Cancer.2020; 51(1): 159.     CrossRef
    • Descriptive Epidemiology of Brain and Central Nervous System Tumours: Results from Iran National Cancer Registry, 2010-2014
      Amir Salimi, Alireza Zali, Amir Saeid Seddighi, Afsoun Seddighi, Shakila Meshkat, Morteza Hosseini, Amir Nikouei, Mohammad Esmaeil Akbari
      Journal of Cancer Epidemiology.2020; 2020: 1.     CrossRef

    • Epidemiologic Study of Gastric Cancer in Iran: A Systematic Review


      Khadijeh Kalan Farmanfarma, Neda Mahdavifar, Soheil Hassanipour, Hamid Salehiniya
      Clinical and Experimental Gastroenterology.2020; Volume 13: 511.     CrossRef
    • Prevalence and demographic characteristics of cancers
      Zahra Tolou-Ghamari
      Clinical Cancer Investigation Journal.2020; 9(1): 13.     CrossRef
    • Incidence of Esophageal Cancer in Iran, a Population-Based Study: 2001–2015
      Rahmatollah Moradzadeh, Parvaneh Golmohammadi, Bahman Ghaitasi, Haidar Nadrian, Athareh Najafi
      Journal of Gastrointestinal Cancer.2019; 50(3): 507.     CrossRef
    • A 12-year trend analysis of the incidence of gastrointestinal cancers in East Azerbaijan: last updated results of an ongoing population-based cancer registry
      Mohammad Hossein Somi, Roya Dolatkhah, Sepideh Sepahi, Mina Belalzadeh, Shahnaz Naghashi, Mohammad Asghari Jafarabadi
      BMC Cancer.2019;[Epub]     CrossRef
    • Trends and risk factors of gastric cancer in Iran (2005–2010)
      Sedigheh Rastaghi, Tohid Jafari-Koshki, Behzad Mahaki, Yousef Bashiri, Kamran Mehrabani, Ali Soleimani
      International Journal of Preventive Medicine.2019; 10(1): 79.     CrossRef
    • Helicobacter pylori cagL amino acid polymorphism D58E59 pave the way toward peptic ulcer disease while N58E59 is associated with gastric cancer in north of Iran
      Mina Rezaee Cherati, Javad Shokri-Shirvani, Ahmad Karkhah, Ramzan Rajabnia, Hamid Reza Nouri
      Microbial Pathogenesis.2017; 107: 413.     CrossRef

    Figure
    • 0
    • 1
    Related articles
    Trends in gastrointestinal cancer incidence in Iran, 2001-2010: a joinpoint analysis
    Image Image
    Figure 1. Trends in the age-standardized incidence rate (ASR) for gastrointestinal cancers (A: stomach, B: colorectal, and C: esophageal) in Iran, 2001-2010.
    Figure 2. Trends in the age-standardized incidence rate (ASR) of gastrointestinal cancers (A:stomach, B: colorectal, and C: esophageal) by age group.

    Figure 1.

    Figure 2.

    Trends in gastrointestinal cancer incidence in Iran, 2001-2010: a joinpoint analysis
    Cancer site Men
    		 Women
    2001
    		 2010
    		 2001
    		 2010
    No. of cases CR ASR No. of cases CR ASR APC No. of cases CR ASR No. of cases CR ASR APC
    Stomach 1,105 3.3 4.18 5,192 13.2 17.06 16.7* 484 1.5 2.41 2,238 6.5 8.85 16.2*
    Colorectal 379 1.3 2.12 3,443 8.8 11.28 20.0* 344 1.2 2.00 2,641 7.7 10.33 20.0*
    Esophageal 858 2.5 3.25 1,693 4.3 5.57 12.0* 405 1.3 2.10 1,378 4.0 5.62 11.2*
    Cancer site, age APC (95% Cl) 2001-2010 Trend 1 APC (95% CI) Trend 2 APC (95% CI) Trend 3 APC (95% CI)
    Men
     Stomach
      40-49 12.4 (0.6, 25.7) 2001-2003 54.2 (-21.8, 204.0) 2003-2008 11.9 (-9.7, 38.7) 2008-2010 -17 (-57.9, 63.7)
      50-59 9.8 (6.3, 13.3) 2001-2003 41.4 (16.4, 71.7) 2003-2008 10.2 (3.6, 17.2) 2008-2010 -15.6 (-30.5, 2.5)
      60-69 12.3 (6.5, 18.4)* 2001-2003 41.5 (6.5, 88.0)* 2003-2010 5.1 (1.2, 9.2) N/A N/A
      70-79 16.6 (12.4, 21.0) 2001-2003 63.4 (30.6, 104.4) 2003-2008 9.6 (2.1, 17.6) 2008-2010 -2.9 (-22.3, 21.5)
      80+ 23.7 (14.3, 33.9) 2001-2004 63.6 (26.3, 112.0) 2004-2010 7.6 (-1.5, 17.4) N/A N/A
      All 16.7 (14.6, 18.8)* 2001-2003 70.4 (52.6, 90.3)* 2003-2008 8.9 (5.1, 12.8)* 2008-2010 -5.1 (-15.0, 6.0)
     Colorectal
      40-49 13.0 (10.4, 15.6)* 2001-2003 46.7 (27.6, 68.6)* 2003-2008 15.1 (10.1, 20.3)* 2008-2010 -16.9 (-27.7, -4.5)*
      50-59 17.2 (11.8, 22.8)* 2001-2003 52.9 (15.0, 103.3)* 2003-2008 17.6 (7.5, 28.7)* 2008-2010 -11.0 (-33.1, 18.3)
      60-69 24.2 (16.1, 32.9)* 2001-2003 62.3 (13.1, 133.1)* 2003-2010 15.1 (9.7, 20.8)* N/A N/A
      70-79 21.0 (15.4, 26.9)* 2001-2004 43.1 (22.7, 66.9)* 2004-2010 11.3 (5.6, 17.2)* N/A N/A
      80+ 21.2 (11.9, 31.3)* 2001-2007 35.9 (24.4.8, 48.4)* 2007-2010 -3.6 (-25.7, 25.2) N/A N/A
      All 20.0 (15.6, 24.6)* 2001-2003 63.3 (30.0, 105.1)* 2003-2008 15.9 (7.8, 24.5)* 2008-2010 -3.8 (-23.4, -0.7)
     Esophageal
      40-49 9.2 (-6.0, 26.8) 2001-2004 42.8 (-10.0, 126.5) 2004-2008 6.2 (-33.1, 38.4) 2008-2010 -22.9(-69.4, 94.1)
      50-59 12.5 (6.5, 18.8)* 2001-2003 64.3 (17.6, 129.6)* 2003-2008 10.8 (-0.3, 23.2) 2008-2010 -20 (-42.7.2, 11.7)
      60-69 14.3 (6.2, 23.1)* 2001-2003 57.7 (6.4, 133.7)* 2003-2010 4.3 (-1.0, 9.9) N/A N/A
      70-79 13.4 (5.2, 22.2)* 2001-2005 31.7 (11.6, 55.5)* 2005-2010 0.6 (-10.6, 13.1) N/A N/A
      80+ 17.5 (6.4, 29.8)* 2001-2003 77.1 (-3.3, 224.4) 2003-2008 15.5 (-4.6, 39.9) 2008-2010 -18.6 (-55.6, 49.0)
      All 12.0 (6.6, 17.7)* 2001-2003 54.6 (14.1, 109.4)* 2003-2008 8.9 (-1.1, 19.9) 2008-2010 -12.8 (-35.7, 18.1)
    Women
     Stomach
      40-49 12.1 (3.4, 21.6) 2001-2004 38.3 (13.0, 69.3) 2004-2008 12.3 (-6.3, 34.6) 2008-2010 -18.5 (-57.3, 55.3)
      50-59 14.6 (8.5, 21.0) 2001-2004 35.8 (13.8, 62.1) 2004-2010 5.3 (-0.9, 11.7) N/A N/A
      60-69 13.1 (5.9, 20.8)* 2001-2004 35.6 (9.5, 68.0)* 2004-2010 3.3 (-3.9, 11.0) N/A N/A
      70-79 16.1 (8.8, 23.9) 2001-2003 40.1 (-1.2, 98.7) 2003-2010 10.0 (5.0, 15.3) N/A N/A
      80+ 18.6 (13.9, 23.5) N/A N/A N/A N/A N/A N/A
      All 16.2 (7.7, 25.4)* 2001-2003 53.3 (2.1, 130.1)* 2003-2010 7.4 (1.7, 13.4)* N/A N/A
     Colorectal
      40-49 18.6 (8.3, 29.8)* N/A N/A N/A N/A N/A N/A
      50-59 25.1 (13.3, 38.2)* 2001-2003 69.3 (-0.3, 187.5) 2003-2010 14.8 (6.9, 23.2)* N/A N/A
      60-69 19.5 (13.3, 26.1)* 2001-2004 52.8 (28.5, 81.8)* 2004-2010 5.7 (-0.3, 12.1) N/A N/A
      70-79 20.2 (15.5, 25.1)* 2001-2004 48.3 (30.1,69.1)* 2004-2010 8.2 (3.6, 13.1)* N/A N/A
      80+ 23.0 (10.9, 36.6)* 2001-2004 60.4 (14.2, 125.3)* 2004-2010 7.8 (-3.9, 20.9) - -
      All 20.0 (18.8, 21.3)* 2001-2003 66.8 (56.4, 78.0)* 2003-2008 13.8 (11.5, 16.1)* 2008-2010 -1.3 (-7.5, 5.3)
     Esophageal
      40-49 6.5 (-1.8, 15.4) 2001-2003 62.7 (-0.4, 165.9) 2003-2008 1.9 (-1.7, 19.0) 2008-2010 -22.3 (-52.4, 27.0)
      50-59 14.0 (1.5, 28.2)* 2001-2003 52.8 (-18.2, 185.6) 2003-2010 4.9 (-3.5, 14.0) N/A N/A
      60-69 13.9 (5.6, 22.9)* 2001-2003 70.8 (14.0, 155.8)* 2003-2010 1.5 (-3.9, 7.1) N/A N/A
      70-79 12.6 (3.7, 22.4)* 2001-2003 52.3 (-8.1, 152.5) 2003-2008 9.7 (-6.5, 28.7) 2008-2010 -11.1 (-46.4, 47.4)
      80+ 15.3 (4.9, 26.8)* 2001-2003 28.7 (20.2, 37.7)* 2003-2010 -21.5(-52.7, 30.4) N/A N/A
      All 11.2 (6.2, 16.5)* 2001-2003 54.5 (16.7, 104.7)* 2003-2008 7.4 (-1.7, 17.4) 2008-2010 -12.7 (-34.1, 15.6)
    Table 1. CRs and ASRs for gastrointestinal cancers in men and women in Iran, 2001-2010

    CR, crude rates (per 100,000); ASR, age-standardized incidence rates (per 100,000); APC, annual percent change of ASRs.

    p<0.05.

    Table 2. Trends in the ASRs for gastrointestinal cancers in Iranian men and women according to a joinpoint analysis by age group (2001-2010)

    ASR, age-standardized incidence rate; APC, annual percentage change of ASRs; CI, confidence interval; N/A, not applicable.

    p<0.05.

    Table 1.

    Table 2.

    Epidemiol Health : Epidemiology and Health
    © Korean Society of Epidemiology.
    TOP